GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
By Elana Gotkine HealthDay Reporter

WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.
Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk. Patients with T2DM initiating GLP-1 RAs or metformin as first-line monotherapy were included (87,229 matched patients per cohort).
The researchers found that compared with metformin, GLP-1 RA use was associated with a significantly lower risk for overall dementia, Alzheimer disease, and nonvascular dementias (adjusted hazard ratios, 0.90, 0.88, and 0.75, respectively). For vascular dementia, no significant difference was observed. Consistent benefit was seen across age and sex in subgroup analyses, with the strongest effect seen among older adults and women.
"Despite limitations such as residual confounding, the findings remain robust and suggest GLP-1 RAs could redefine T2DM-related dementia prevention strategies, warranting further randomized controlled trials to confirm these results," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-24 06:00
Read more

- Antidepressant Withdrawal Not As Severe As Thought, Evidence Review Says
- DropScreen, ViewAllergy39 Not Equally Effective for Detecting Allergens
- Susan Monarez Advances in Process to Lead CDC
- FDA Approves Ekterly (sebetralstat) the First and Only Oral On-demand Treatment for Hereditary Angioedema (HAE)
- RFK Jr. Fires Two Trump-Appointed Senior Officials in Ongoing HHS Restructuring
- WHO, UNICEF Say More Than 14 Million Infants Worldwide Remain Unvaccinated
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions